Pfizer Cools To Tax Inversion After Nixed Allergan Deal
By Erin Coe ( May 4, 2016, 9:25 PM EDT) -- Pfizer Inc. said Tuesday it isn't inclined to seek another inversion transaction after it scrapped a proposed $160 billion merger with Irish drugmaker Allergan in April in light of the U.S. Department of Treasury's new rules aimed at curbing the tax-motivated deal structure....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.